VCAM-1 Upregulation Contributes to Insensitivity of Vemurafenib in BRAF-Mutant Thyroid Cancer

Vemurafenib, an inhibitor of mutant BRAF activity, is a promising anticancer agent for patients with BRAF-mutant metastatic melanoma. However, it is less effective in BRAF-mutant thyroid cancer, and the reason for this discrepancy is not yet fully elucidated. By RNA sequencing analysis, we identifie...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Transl Oncol
Glavni autori: Chen, Shitu, Su, Xingyun, Jiang, Xiaoxia, Zhang, Tuo, Min, Irene, Ding, Yongfeng, Wang, Xumeng, Mao, Zhuochao, Cao, Jiang, Teng, Xiaodong, Fahey, Thomas J., Wang, Weibin, Teng, Lisong
Format: Artigo
Jezik:Inglês
Izdano: Neoplasia Press 2020
Teme:
Original article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6948368/
https://ncbi.nlm.nih.gov/pubmed/31911278
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.tranon.2019.10.007
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items